Mobile

Pharmacokinetics and safety of agomelatine in children (from 7 to less than 12 years) and adolescents (from 12 to less than 18 years) with Depressive or Anxiety Disorder

Mise à jour : Il y a 4 ans
Référence : EUCTR2012-003404-12

Femme et Homme

  • | Pays :
    • -
  • | Organes :
    • -
  • | Spécialités :
    • -

Extrait

The primary objective is to evaluate pharmacokinetics of 3 doses of agomelatine in patients from 7 to less than 18 years suffering from Depressive or Anxiety Disorder.

Critère d'inclusion

  • Depressive or Anxiety Disorder

Liens